NSCLC Stage IV Clinical Trial
Official title:
A Multi-center Phase II Study of Ipatasertib in Combination With Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy (Ipat-Lung)
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be an effective strategy. Ipatasertib is a novel adenosine triphosphate (ATP)-competitive inhibitor that has demonstrated robust and selective targeting of protein kinase B (PKB, also known as AKT) in cancer patients. Importantly, evidence from preclinical studies has demonstrated that AKT inhibitors (e.g. ipatasertib) can enhance the therapeutic effect of chemotherapy as well as immunotherapy via modulating Phosphatidylinositol 3-kinase (PI3'K)-AKT activity.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05543330 -
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04106180 -
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT05215548 -
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
|
Phase 2 | |
| Recruiting |
NCT04042558 -
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
|
Phase 2 | |
| Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT04027647 -
Phase 2 Study of Dacomitinib in NSCLC
|
Phase 2 | |
| Recruiting |
NCT04768491 -
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
|
||
| Not yet recruiting |
NCT04492969 -
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
|
||
| Recruiting |
NCT04116918 -
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
|
||
| Terminated |
NCT03411473 -
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
|
Phase 2 | |
| Recruiting |
NCT03564197 -
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
|
N/A | |
| Not yet recruiting |
NCT06219317 -
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT04604470 -
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
|
||
| Recruiting |
NCT05132218 -
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
|
||
| Not yet recruiting |
NCT04136535 -
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
|
Phase 2 | |
| Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT06339554 -
Alectinib-induced Endocrine Toxicity
|
||
| Active, not recruiting |
NCT04549428 -
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
|
Phase 2 | |
| Recruiting |
NCT03647956 -
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
|
Phase 2 | |
| Recruiting |
NCT04180501 -
SRS Sequential Sindilimab in Brain Metastasis of NSLSC
|
Phase 2 |